SignatureFD’s NextCure NXTC Stock Holding History

SignatureFD’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8	Closed	-$1K	–	3160
2021 Q2	$1K	Sell	8 -20	-71%	-$2.05K	﹤0.01%	2788
2021 Q1	$3K	Buy	+28	New	+$4.05K	﹤0.01%	2362
2020 Q3	–	Sell	-4	Closed	-$1K	–	2706
2020 Q2	$1K	Buy	+4	New	+$1.52K	﹤0.01%	2347

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SignatureFD's NXTC Position: Q3 2021 in Review

SignatureFD sold out of NextCure (NXTC) in Q3 2021, closing a stake of 8 shares — an estimated $1K sold.

SignatureFD first reported a position in NXTC in Q2 2020 and held it in 3 quarters. The position peaked at $3K in Q1 2021. 71 funds tracked by Wall St. Rank hold NXTC as of Q3 2021.

SignatureFD reported no remaining NextCure position as of Q3 2021 after selling out during the quarter.
SignatureFD sold 8 NextCure shares in Q3 2021, an estimated $1K.
SignatureFD first reported a position in NextCure in Q2 2020 and held it in 3 quarters.
SignatureFD's NextCure position peaked at $3K in Q1 2021.
71 funds tracked by Wall St. Rank held NextCure as of Q3 2021.

Based on SignatureFD's 13F filing for Q3 2021, filed 28 Oct 2021.